E7386

Phase 1Small molecule

Eisai

E7386 is one of 84 small molecule programs targeting Colorectal Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Solid TumorActive, not recruiting

Advanced NeoplasmsActive, not recruiting

Colorectal CancerPhase 1

Active, not recruiting

Solid TumorPreclinical

Active, not recruiting

Advanced NeoplasmsPhase 1

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Nubeqa

Bayer

Preclinical

2 2

DATROWAY

Daiichi Sankyo

Preclinical

1 3

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 4

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 5

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

E7386

Eisai

Phase 1

7 7

Ifinatamab Deruxtecan

Daiichi Sankyo

Preclinical

1 8

Carboplatin AUC-5

Merck & Co.

Preclinical

1 9

Soc

Pfizer

Preclinical

1 10

Interleukin 2

EEssen Biotech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Colorectal Cancer

NCT03833700

Phase 1Active, not recruiting

Advanced Neoplasms

NCT03264664

PreclinicalActive, not recruiting

Endometrial Neoplasms

NCT04008797

Clinical

Trials by Indication[1]

ART1 trial

A Food-Effect Study of E7386 in Healthy Participants

Completed· Eisai logo

Eisai·Phase 1·NCT03996226·17 enrolled

Colorectal Cancer1 trial

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Active, not recruiting· Eisai logo

Eisai·Phase 1·NCT03833700·70 enrolled

Advanced Neoplasms1 trial

Study of E7386 in Participants With Selected Advanced Neoplasms

Active, not recruiting· Eisai logo

Eisai·Phase 1·NCT03264664·60 enrolled

Adult1 trial

A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants

Withdrawn· Eisai logo

Eisai·Phase 1·NCT04840927

Absorption1 trial

A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants

Completed· Eisai logo

Eisai·Phase 1·NCT05607537·15 enrolled

2 more indications

Pembrolizumab1 trial

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Completed· Eisai logo

Eisai·Phase 1/2·NCT05091346·89 enrolled

Endometrial Neoplasms1 trial

An Open-label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors

Active, not recruiting· Eisai logo

Eisai·Preclinical·NCT04008797·301 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for E7386. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — E7386 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for E7386. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eisai

E7386

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

ART1 trial

Colorectal Cancer1 trial

Advanced Neoplasms1 trial

Adult1 trial

Absorption1 trial

Pembrolizumab1 trial

Endometrial Neoplasms1 trial

References

Drug Info

Quick Facts

Related News